Fremanezumab for the Preventive Treatment of Chronic Migraine

2017793 citationsJournal Article

Authors

Stephen D. Silberstein · Thomas Jefferson University

David W. Dodick · Mayo Clinic Hospital

Marcelo E. Bigal · Teva Pharmaceuticals (United States)

Paul Yeung · Teva Pharmaceuticals (United States)

Peter J. Goadsby · King's College London

Tricia Blankenbiller · Teva Pharmaceuticals (United States)

Melissa Grozinski‐Wolff

Abstract

Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequency of headache than placebo in this 12-week trial. Injection-site reactions to the drug were common. The long-term durability and safety of fremanezumab require further study. (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT02621931 .).

Topics & Keywords

Migraine and Headache Studies Sympathectomy and Hyperhidrosis Treatments Neurological Disorders and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 377, Issue 22, pp. 2113-2122

DOI: 10.1056/nejmoa1709038

Field-Weighted Citation Impact: 52.64